

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8241250

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CARDIORENAL SYSTEMS, INC.	07/22/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	REPRIEVE CARDIOVASCULAR, INC.
<b>Street Address:</b>	C/O PERKINS COIE LLP
<b>Internal Address:</b>	1201 THIRD AVENUE SUITE 4900
<b>City:</b>	SEATTLE
<b>State/Country:</b>	WASHINGTON
<b>Postal Code:</b>	98101
<b>PROPERTY NUMBERS Total: 4</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	8007460
Patent Number:	8075513
Patent Number:	9526833
Patent Number:	10045734
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(206)359-4461
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2063598000
<b>Email:</b>	patentprocurement@perkinscoie.com
<b>Correspondent Name:</b>	PERKINS COIE LLP
<b>Address Line 1:</b>	1201 THIRD AVENUE SUITE 4900
<b>Address Line 4:</b>	SEATTLE, WASHINGTON 98101
<b>ATTORNEY DOCKET NUMBER:</b>	140115.8000
<b>NAME OF SUBMITTER:</b>	CHELSEA M. CRAZE
<b>SIGNATURE:</b>	/ Chelsea M. Craze /
<b>DATE SIGNED:</b>	10/25/2023
<b>Total Attachments: 5</b>	
source=Assignment_Cardio_To_Reprieve#page1.tif	

source=Assignment\_Cardio\_To\_Reprieve#page2.tif  
source=Assignment\_Cardio\_To\_Reprieve#page3.tif  
source=Assignment\_Cardio\_To\_Reprieve#page4.tif  
source=Assignment\_Cardio\_To\_Reprieve#page5.tif

## PATENT ASSIGNMENT

This Patent Assignment (this "Assignment") is entered into as of July 22, 2020, by and between Reprieve Cardiovascular, Inc., a Delaware corporation ("Assignee"), and CardioRenal Systems, Inc., a Delaware corporation ("Assignor").

A. Assignor and Assignee are parties to that certain Contribution Agreement dated as of the date hereof (the "Contribution Agreement"), pursuant to which Assignor has agreed to convey and Assignee has agreed to acquire, among other assets, all of the United States, European and International patents and patent applications set forth on Schedule A attached hereto (collectively, the "Patents").

B. Assignor is the sole and exclusive owner of the right, title and interest in, to and under the Patents, and Assignee wishes to acquire and Assignor wishes to transfer to Assignee all right, title and interest in, to and under the Patents.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby convey, transfer, assign and deliver to Assignee, the entire right, title and interest in and to the Patents and the inventions they claim (including subject matter capable of being reduced to a patent claim in a reissue or reexamination proceeding relating to any of the Patents and subject matter that could have been included as a claim in any of the Patents), and any and all continuations, divisionals, continuations-in-part, reissues, reexaminations, extensions, international applications or foreign equivalents thereof, as applicable, which may be obtained therefrom for its own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made; together with all income, royalties, damages or payments due or payable as of the date hereof or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patents, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

Assignor authorizes and requests the appropriate governmental authority to record Assignee as owner of the Patents, including any continuations, divisions, continuations-in-part, reissues, reexaminations, international applications or extensions thereof, and to issue any and all letters patent thereon to Assignee, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.

*[Signature Page Follows]*

IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be executed as of the date first written above by their respective authorized representatives.

ASSIGNEE:

**REPRIEVE CARDIOVASCULAR, INC.**

DocuSigned by:  
By: Hanson Gifford  
Name: Hanson Gifford  
Title: Director

ASSIGNOR:

**CARDIORENAL SYSTEMS, INC.**

By: \_\_\_\_\_  
Name: Jim Dillon  
Title: President and Chief Executive Officer

*[Signature Page to Patent Assignment]*

IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be executed as of the date first written above by their respective authorized representatives.


ASSIGNEE:

**REPRIEVE CARDIOVASCULAR, INC.**

By: \_\_\_\_\_  
Name: Hanson Gifford  
Title: Director

ASSIGNOR:

**CARDIORENAL SYSTEMS, INC.**

By:  \_\_\_\_\_  
Name: Jim Dillon  
Title: President and Chief Executive Officer

*[Signature Page to Patent Assignment]*

**SCHEDULE A**  
**PATENTS**

- CRS's interest in all intellectual property identified in Exhibit B to that certain License Agreement by and between the Company and CRS, of even date herewith, in each case, as of the date hereof.
- U.S. Patent No. 10,639,419
- U.S. Patent Application 16/863,824
- U.S. Patent Application 16/053,056
- U.S. Patent Application 16/153,380
- U.S. Patent Application 16/544,975
- U.S. Provisional Patent Application 62/945,058
- U.S. Provisional Patent Application 62/865,557 (abandoned) and to be refiled after revision of application
- U.S. Patent Application 62/864,784 (abandoned), and refiled as Application 63/044,739
- International Patent Application PCT/US2015/20196 (WO2015142617)
- European Patent Application 3119284 (EP application 15765772.7)
- European Patent Application 3278833 (EP application 17001541.6)
- International Patent Application PCT/US2019/032641 (WO 2019/222485)

**EXHIBIT B**  
**LICENSED PATENTS**

U.S. Patent 8,007,460

U.S. Patent 8,075,513

U.S. Patent 9,526,833

U.S. Patent 10,045,734

US Patent 10,639,419

U.S. Patent Application 16/863,824

Japanese Patent 4782134

Canadian Patent 2579829

European Patent 2010268

European Patent 1804889

European Patent 2073887

European Patent 2010251

European Patent Application 3278833